Myeloma Accelerator Challenge (MAC)
Funds multicenter translational myeloma research networks for high risk disease targets.
The Multiple Myeloma Research Foundation's Myeloma Accelerator Challenge sits under the foundation's research portfolio as a cooperative-agreement program for multicenter translational networks in multiple myeloma. The 2023 cycle carried $21 million in total funding across three awards, each set at up to $7 million over three years, and the work was organized around large academic cancer centers rather than single-lab projects. The program concentrates on two hard clinical questions: improving first-line therapy for high-risk newly diagnosed multiple myeloma and sharpening identification of high-risk smoldering disease. Eligibility is consortium-based, with universities, nonprofits, and research organizations able to participate while for-profit applicants and individuals are out. The funded networks in 2023 were anchored at Emory University, Erasmus Medical Center, and Mount Sinai, which points to a review process that favors institutional depth and partner density. MAC is not a rolling small-project call. It is a high-commitment network award that moves through direct grants-team contact rather than a public application portal, and the last public cycle was in 2023. The European awardee in Rotterdam shows that the foundation can back global collaborations when the scientific team and consortium structure are strong enough to match the program's translational aim.
No upcoming rounds verified. Cadence: One-off.